Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Steven Golombek (NPI 1760449565)

Field	Value
Entity Type	Individual
Organization	Steven Golombek
Address	600 Mount Pleasant Ave
City	Dover
State	NJ
ZIP	07801
Taxonomy	Rheumatology Physician
NPI Enumerated	April 27, 2006

Payer Source	Total Paid
Medicare	$4.2M
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer: lifetime Medicare revenue is $4.2M while Medicaid billing is none, indicating no Medicaid billing on file. For payers and network planners this signals the provider’s revenue and patient mix are driven almost entirely by Medicare beneficiaries rather than dual or Medicaid populations.

Revenue is highly concentrated in a small set of physician‑administered drugs: the top three Medicare codes (J0897, J0717, J3262) account for 49.2% of the provider’s total Medicare revenue. Those top three contributors are J0897 ($762.5K, 18.0%), J0717 ($727.2K, 17.2%), and J3262 ($594.4K, 14.0%), underscoring dependence on high‑volume biologic injections.

The code mix indicates a rheumatology practice structured around in‑office administration of biologic and infusion therapies. High‑revenue drug codes such as J0897 (denosumab), J0717 (certolizumab pegol), J3262 (tocilizumab) and J0129 (abatacept) alongside infusion/administration codes 96401 ($157.1K), 96413 ($96.6K), and 96415 ($15.4K) show the provider delivers substantial on‑site injectable and infusion services rather than primarily prescribing self‑administered medications.

This provider shows dominant national standing on several drug codes: J0897 ranks #35 of 10057 providers nationally (100th percentile; extreme outlier) and J0717 ranks #37 of 848 providers nationally (96th percentile; notably above typical national volume). J3262 also ranks high at #31 of 618 providers nationally (95th percentile; notably above typical national volume). Those ranks indicate the provider is a major national outlier in physician‑administered biologic volume for these products.

Office evaluation and management activity is high and complements infusion services: 99214 generated $278.8K from 2.8K claims (6.6% of Medicare revenue) and ranks #336 of 479517 providers nationally (100th percentile; extreme outlier), while 99213 produced $107.8K from 1.5K claims and ranks at the 100th percentile as well. The combination of elevated E/M volumes with infusion administrations suggests sustained ambulatory follow‑up and monitoring associated with chronic biologic therapy.

Several administration and procedure codes are statistical outliers indicative of concentrated infusion operations: 96401 is an extreme outlier (rank #6 of 3868 providers nationally, 100th percentile) and procedure codes for intra‑articular injections such as 20610 (rank #395 of 39752, 99th percentile; extreme outlier) and J7324 (rank #27 of 1509, 98th percentile; extreme outlier) further illustrate unusually high procedure volumes compared with peers. These outlier labels point to a practice workflow built around procedural and infusion throughput.

The provider’s NPI tenure is long‑standing: enumerated 2006-04-27 (~20 years ago), which supports interpretation of these volumes as the output of an established clinical practice rather than a new entrant. Long tenure combined with concentrated biologic and infusion billing suggests an entrenched service line and operational experience in office‑based administrations.

From a payer risk and contracting perspective, the heavy reliance on physician‑administered biologics and infusion/chemotherapy administration codes implies revenue sensitivity to drug reimbursement changes and utilization management policies. Given the top three codes account for 49.2% of Medicare revenue and multiple codes are national outliers, payers should expect that any changes to coverage or reimbursement for these specific drugs or infusion services could materially affect this provider’s Medicare revenue stream.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

37 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0897	Injection, denosumab, 1 mg	42,360	$20	$762.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	181,800	$1	$727.2K
J3262	Injection, tocilizumab, 1 mg	118,880	$10	$594.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	16,990	$30	$560.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,820	$100	$278.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,310	$30	$216.1K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	2,380	$70	$157.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	14,200	$10	$156.2K
J3111	Injection, romosozumab-aqqg, 1 mg	17,640	$10	$141.1K
J9312	Injection, rituximab, 10 mg	1,950	$60	$120.9K

Showing 1–10 of 37

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 37 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Steven Golombek — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

37 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	6	40	7,600	$30	$297K
J9312	3	10	3,960	$60	$242.7K
J3262	1	20	33,800	$1	$227.5K
J0717	3	60	42,300	$1	$219.5K
J1602	16	40	12,580	$10	$165.7K
J1745	3	30	3,670	$30	$131.9K
J3111	8	30	12,600	$10	$107.3K
Q5104	3	10	3,190	$30	$99.4K
J0897	2	380	3,060	$20	$87.8K
96413	10	230	190	$110	$26.6K

Showing 1–10 of 37

Related Providers

Other providers that share a Tax Identification Number (TIN) with Steven Golombek, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jeanne Pare	NJ	Rheumatology Physician	$1.4M	$0
Stephen Bigelsen	NJ	Allergy & Immunology (Internal Medicine) Physician	$152.6K	$0

Nearby Providers

Other providers in the same ZIP code as Steven Golombek, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	NJ	Home Health Agency	$0	$11.8M
Zufall Health Center, Inc	NJ	Federally Qualified Health Center (FQHC)	$0	$10.6M
City Medical Transport Corporation	NJ	Non-emergency Medical Transport (VAN)	$1.1M	$70.8K
Eric Mann	NJ	Ophthalmology Physician	$858.5K	$46.4K
Vincent Gengaro Iii	NJ	Physical Therapist	$382.2K	$0
Joel Spielman	NJ	Orthopaedic Surgery Physician	$147.3K	$0
Bivin Thomas	NJ	Internal Medicine Physician	$65.7K	$0
Roger Warn	NJ	Registered Dietitian	$11.9K	$0

Steven Golombek — Billing Profile & Reimbursement Data

Sign up for Steven Golombek — Billing Profile & Reimbursement Data policy alerts

Steven Golombek — Billing Profile & Reimbursement Data

Sign up for Steven Golombek — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References